Asarina Pharma AB (publ) releases Year-End Report 2022

(Stockholm, 27 February 2023.) Asarina Pharma today announces that it has released its Year End Report 2022. In the second half of 2022 the company continued its Phase IIa study in Sepranolone for Tourette Syndrome, on schedule, completing Last Patient Last Visit on February 1, less than 12 months after commencement. The patient dropout rate remained unexpectedly low throughout the study. Results continue to be expected at the end of March 2023.FINANCIAL HIGHLIGHTS · Operating costs (MSEK 6.7) well under control  · Cash reserves at year-end (MSEK 13.6) enough to finance completion